Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.

Literature DB >> 16818909

Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.

Anthony Hodsman¹, Alexandra Papaioannou.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2006 PMID： 16818909 PMCID： PMC1482768 DOI： 10.1503/cmaj.060624

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

8 in total

1. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat--which of these should we use?

Authors: Edna Schechtman
Journal: Value Health Date: 2002 Sep-Oct Impact factor: 5.725

Review 2. Parathyroid hormone for the treatment of osteoporosis: a systematic review.

Authors: Ann Cranney; Alexandra Papaioannou; Nicole Zytaruk; David Hanley; Jonathan Adachi; David Goltzman; Timothy Murray; Anthony Hodsman
Journal: CMAJ Date: 2006-07-04 Impact factor: 8.262

Review 3. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

Authors: Anthony B Hodsman; Douglas C Bauer; David W Dempster; Larry Dian; David A Hanley; Steven T Harris; David L Kendler; Michael R McClung; Paul D Miller; Wojciech P Olszynski; Eric Orwoll; Chui Kin Yuen
Journal: Endocr Rev Date: 2005-03-15 Impact factor: 19.871

Review 4. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors: Jacques P Brown; Robert G Josse
Journal: CMAJ Date: 2002-11-12 Impact factor: 8.262

5. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

Authors: J Reginster; H W Minne; O H Sorensen; M Hooper; C Roux; M L Brandi; B Lund; D Ethgen; S Pack; I Roumagnac; R Eastell
Journal: Osteoporos Int Date: 2000 Impact factor: 4.507

6. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors: S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal: JAMA Date: 1999-10-13 Impact factor: 56.272

7. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245

8. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors: D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal: Lancet Date: 1996-12-07 Impact factor: 79.321

8 in total

9 in total

Review 1. Parathyroid hormone analogues in the treatment of osteoporosis.

Authors: Marius E Kraenzlin; Christian Meier
Journal: Nat Rev Endocrinol Date: 2011-07-12 Impact factor: 43.330

2. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.

Authors: L Jacob; M Dreher; K Kostev; P Hadji
Journal: Osteoporos Int Date: 2015-10-30 Impact factor: 4.507

3. Osteoanabolics.

Authors: Vishal Gupta; Mitul Abhaykumar Shah; Sagar Kirtibhai Shah; Jinen Mukeshbhai Shah
Journal: Indian J Endocrinol Metab Date: 2012-05

4. Antiosteoporotic Activity of Dioscorea alata L. cv. Phyto through Driving Mesenchymal Stem Cells Differentiation for Bone Formation.

Authors: Kang-Yung Peng; Lin-Yea Horng; Hui-Ching Sung; Hui-Chuan Huang; Rong-Tsun Wu
Journal: Evid Based Complement Alternat Med Date: 2011-06-29 Impact factor: 2.629

Review 5. Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.

Authors: Jean-Philippe Bonjour; Wendy Kohrt; Régis Levasseur; Michelle Warren; Susan Whiting; Marius Kraenzlin
Journal: Nutr Res Rev Date: 2014-11-14 Impact factor: 7.800